Fibrobiologics Inc expected to post a loss of 72 cents a share - Earnings Preview
Fibrobiologics Inc <FBLG.OQ> expected to post a loss of 72 cents a share - Earnings Preview
Fibrobiologics Inc FBLG.OQ FBLG.O is expected to show no change in quarterly revenue when it reports results on July 29 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Fibrobiologics Inc is for a loss of 72 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fibrobiologics Inc is $13.50, about 1,796.1% above its last closing price of $0.71
This summary was machine generated July 27 at 11:06 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts